Effect of peptides on neutralization of anti—Factor Xa activity of UFH in patient plasma
Patient number | 1-H | 2-H | 3-H |
Anti—Factor Xa activity at collection, U/mL | 0.36 | 0.49 | 0.27 |
U/mL anti-FXa activity neutralized in the presence of 6 mg/mL peptide | |||
Peptide | |||
Protamine | 0.357 ± 0.030 | 0.408 ± 0.011 | 0.274 ± 0.010 |
(ARKKAAKA)4 | 0.282 ± 0.196 | 0.254 ± 0.053 | 0.299 ± 0.050 |
C(ARKKAAKA)4C | 0.099 ± 0.064 | 0.248 ± 0.011 | 0.172 ± 0.005 |
(ARKKAAKA)3ARKKCAKA | 0.368 ± 0.022 | 0.324 ± 0.015 | 0.187 ± 0.020 |
ARKKAAKA(A16)ARKKAAKA | 0.020 ± 0.016 | 0.017 ± 0.018 | 0 |
(ARKKAAKA)3VLVLVLVL* | 0.242 ± 0.006 | 0.421 ± 0.040 | 0.285 ± 0.166 |
(ARKKARA)6 | 0.228 ± 0.033 | 0.317 ± 0.082 | 0.176 ± 0.003 |
(ARKKAAKA)3(VL)3 | 0.203 ± 0.013 | 0.368 ± 0.033 | 0.195 ± 0.005 |
(VL)2(ARKKAAKA)3ARKKCAKA | 0.228 ± 0.019 | 0.324 ± 0.025 | 0.207 ± 0.016 |
Patient number | 1-H | 2-H | 3-H |
Anti—Factor Xa activity at collection, U/mL | 0.36 | 0.49 | 0.27 |
U/mL anti-FXa activity neutralized in the presence of 6 mg/mL peptide | |||
Peptide | |||
Protamine | 0.357 ± 0.030 | 0.408 ± 0.011 | 0.274 ± 0.010 |
(ARKKAAKA)4 | 0.282 ± 0.196 | 0.254 ± 0.053 | 0.299 ± 0.050 |
C(ARKKAAKA)4C | 0.099 ± 0.064 | 0.248 ± 0.011 | 0.172 ± 0.005 |
(ARKKAAKA)3ARKKCAKA | 0.368 ± 0.022 | 0.324 ± 0.015 | 0.187 ± 0.020 |
ARKKAAKA(A16)ARKKAAKA | 0.020 ± 0.016 | 0.017 ± 0.018 | 0 |
(ARKKAAKA)3VLVLVLVL* | 0.242 ± 0.006 | 0.421 ± 0.040 | 0.285 ± 0.166 |
(ARKKARA)6 | 0.228 ± 0.033 | 0.317 ± 0.082 | 0.176 ± 0.003 |
(ARKKAAKA)3(VL)3 | 0.203 ± 0.013 | 0.368 ± 0.033 | 0.195 ± 0.005 |
(VL)2(ARKKAAKA)3ARKKCAKA | 0.228 ± 0.019 | 0.324 ± 0.025 | 0.207 ± 0.016 |
Blood was collected from patients treated with continuous infusion of UFH and the anti—Factor Xa activity was monitored as described in the text. All data are for assays with 6 μg/mL peptide.
The data for the most effective peptide, (ARKKAAKA)3VLVLVLVL.